TickerTalks
Browse all tickers →
TickerTalks›$AZN
AZAZN

AstraZeneca PLC

$AZN·$252B·Drug Manufacturers - General·Healthcare
$162.70-1.3%YTD-15.9%1Y+0.4%
Mentions · last 7 days
2026-08-29: 4 posts2026-08-30: 12 posts2026-08-31: 18 posts2026-09-01: 26 posts2026-09-02: 12 posts2026-09-03: 8 posts2026-09-04: 18 posts98+9%
Price updated 11h ago·X counts updated 10h ago
AZAZN
$AZNAstraZeneca PLC
$162.70-1.26%98 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AZN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-09-04

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

AstraZeneca is the diversified pharma with a pipeline win and a pipeline miss — Tagrisso combo hit primary, TEZSPIRE positive in EoE, but eplontersen failed.

AstraZeneca is one of the largest pharma companies globally, running oncology (Tagrisso, Enhertu), respiratory (TEZSPIRE), and cardiovascular franchises. This week's pipeline readouts produced a genuinely two-sided set of data points.

  • Growth is steady with real pipeline: Q1 revenue was $15.3B, up 13% YoY, with the prior three quarters running +4%, +12%, +12% — high-single-digit to low-double-digit growth at $60B ARR, and gross margin at 82% with operating margin at 28% supports the compounder framing at 27x P/E.
  • The pipeline scored major wins: Tagrisso combo hit primary in first-line MET-overexpressing lung cancer (a large addressable population expansion) AND TEZSPIRE hit positive Phase 3 in eosinophilic esophagitis (a genuinely new indication for the respiratory franchise) — two positive Phase 3s in the same week is a rare cluster and both are meaningfully additive to the peak-sales base.
  • The offset is real: CARDIO-TTRansform eplontersen failed with Ionis raising broader silencer-drug questions, and AZN's LUMINARA Phase 2b readout is being flagged as a related question mark — meaning one high-profile miss offsets the two wins in the narrative, which explains why the tape is stalled near the middle of the range rather than breaking out.

October 30 Q3 earnings is the confirmation — a print sustaining revenue growth near 10% with Tagrisso and TEZSPIRE trajectory extending validates the pipeline-wins narrative. Another pipeline miss or an FDA setback on TAGRISSO combo submission is the invalidator; watch Enhertu global launch cadence and any silencer-drug related updates.

Agrees with X sentimentThe mixed X sentiment matches the setup — the Tagrisso combo primary hit and TEZSPIRE positive Phase 3 in eosinophilic esophagitis are real wins, and the CARDIO-TTRansform eplontersen failure raising broader silencer-drug questions is a legitimate offset that keeps the tape range-bound.

What to watch: October 30 Q3 earnings — revenue growth near 10% with Tagrisso and TEZSPIRE trajectory extending validates the pipeline-wins narrative. Another pipeline miss or FDA setback on Tagrisso combo submission is the invalidator; watch Enhertu global launch.

On the calendar: 2026-10-30 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment14 posts analyzed · as of 2026-09-04

$AZN (AstraZeneca) chatter is bearish. STAT autopsy of failed CARDIO-TTRansform (Wainua/eplontersen) study raises broader questions about silencer drugs. Cardiovascular mortality and events data don't look great vs vutrisiran. Small bullish note: AZN Tagrisso combo succeeds in first-line MET-overexpressing lung cancer study. TECX under pressure following AZN LUMINARA Phase 2b readout at ESC. Bear tone dominates ATTR-CM franchise.

Read the AI verdict + X sentiment for $AZN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large pharma/biotech with strong oncology (Tagrisso, Enhertu), cardiovascular, and respiratory drug portfolios.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AZN.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $AZN

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the .

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+46.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
27.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
12.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 27, 2026$2.63$2.50+5.2%
Q1 2026Apr 29, 2026$2.58$2.57+0.4%
Q4 2025Feb 10, 2026$2.12$2.09+1.4%
Q3 2025Nov 6, 2025$2.38$2.28+4.4%
Next earningsFri, Oct 30·consensus EPS $2.60

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.3B+12.5%82.5%27.8%$1.99$1.8B
Q4 FY25$15.5B+4.1%79.9%19.2%$1.51$1.4B
Q3 FY25$15.2B+12.0%81.6%23.6%$1.63$4.4B
Q2 FY25$14.5B+11.7%82.9%24.3%$1.58$1.5B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$63.3B$62.2B – $64.1B$10.25$10.08 – $10.3417
FY27$67.5B$64.4B – $68.6B$11.50$11.27 – $11.6818
FY28$71.8B$67.4B – $75.2B$12.79$9.70 – $14.0421
FY29$77.4B$73.5B – $79.6B$14.87$13.91 – $15.4110
FY30$82.3B$78.2B – $84.6B$16.65$15.57 – $17.2510

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.25%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-11.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.215-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 20Mani SharmaSee Remarks11.9K sh$2.2M
+ 5 other (5 awards) in window

See when $AZN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 193
+ 60 other (56 6-Ks · 2 25-NSEs · 1 11-K · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancerbusinesswire.com·14h agoAZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbackszacks.com·3d agoAZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goalzacks.com·3d agoAstraZeneca's $80 Billion Plan Gets Another Tagrisso Wingurufocus.com·4d agoAstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancerbusinesswire.com·4d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$JNJ$LLY$NVO$PFE$ABBV$MRK$NVS$BMY
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport